Brevan Howard Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Brevan Howard Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,598	Closed	-$505K	–	2187
2025 Q3	$505K	Sell	7,598 -19,396	-72%	-$1.1M	﹤0.01%	1290
2025 Q2	$1.49M	Buy	26,994 +10,880	+68%	+$522K	0.01%	869
2025 Q1	$779K	Buy	+16,114	New	+$675K	0.01%	587
2024 Q3	–	Sell	-8,971	Closed	-$311K	–	1376
2024 Q2	$311K	Buy	+8,971	New	+$263K	﹤0.01%	764
2024 Q1	–	Sell	-11,806	Closed	-$271K	–	1288
2023 Q4	$271K	Buy	+11,806	New	+$207K	﹤0.01%	764

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Brevan Howard Capital Management's PTGX Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 7,598 shares — an estimated $505K sold.

Brevan Howard Capital Management first reported a position in PTGX in Q4 2023 and held it in 5 quarters. The position peaked at $1.49M in Q2 2025. 313 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

Brevan Howard Capital Management reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
Brevan Howard Capital Management sold 7,598 Protagonist Therapeutics shares in Q4 2025, an estimated $505K.
Brevan Howard Capital Management first reported a position in Protagonist Therapeutics in Q4 2023 and held it in 5 quarters.
Brevan Howard Capital Management's Protagonist Therapeutics position peaked at $1.49M in Q2 2025.
313 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.